Open AccessImproving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS‐II DCIS)
Author(s) -
Juraskova I,
Butow P,
Lopez A,
Seccombe M,
Coates A,
Boyle F,
McCarthy N,
Reaby L,
Forbes JF
Publication year - 2008
Publication title -
health expectations
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.314
H-Index - 74
eISSN - 1369-7625
pISSN - 1369-6513
DOI - 10.1111/j.1369-7625.2008.00498.x
Subject(s) - breast cancer , medicine , clinical trial , family medicine , informed consent , randomized controlled trial , ibis , gynecology , tamoxifen , blinding , alternative medicine , cancer , pathology , paleontology , biology
Background Patients and clinicians report difficulties with the process of informed consent to clinical trials and audiotape audits show that critical information is often omitted or poorly presented. Decision aids (DAs) may assist in improving consent. Aims This study piloted a DA booklet for a high priority breast cancer prevention trial, IBIS‐II DCIS, which compares the efficacy of an aromatase inhibitor (anastrozole) with tamoxifen in women who have had surgery for ductal carcinoma in situ (DCIS). Method Thirty‐one Australian women participating in the IBIS‐I breast cancer prevention trial and who are currently in follow‐up agreed to read the IBIS‐II DCIS participant information sheet and the DCIS DA booklet, complete a set of standardized questionnaires, and provide feedback on the DA via a semi‐structured phone interview. Results Women found the DA helpful in deciding about trial participation, reporting that it aided their understanding over and above the approved IBIS‐II DCIS participant information sheet and was not anxiety provoking. Women’s understanding of the rationale and methods of clinical trials and the IBIS‐II DCIS trial was very good; with more than 80% of items answered correctly. The only areas that were not understood well were the concepts of randomization and blinding. Conclusions This study suggests that the DA will be acceptable to and valued by potential participants in the IBIS‐II DCIS study. The revised DA is currently being evaluated prospectively in a randomized controlled trial. If successful, such DAs could transform the consent process to large clinical trials and may also reduce dropout rates.